Suppr超能文献

HbA1c 的个体内变异性:系统评价和荟萃分析。

Within-subject variation of HbA1c: A systematic review and meta-analysis.

机构信息

Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.

出版信息

PLoS One. 2023 Aug 2;18(8):e0289085. doi: 10.1371/journal.pone.0289085. eCollection 2023.

Abstract

BACKGROUND

Glycosylated haemoglobin (HbA1c) measurement is used to diagnose and to guide treatment of diabetes mellitus. Within-subject variability in measured HbA1c affects its clinical utility and interpretation, but no comprehensive systematic review has described within-subject variability.

METHODS

A systematic review and meta-analysis was performed of within-subject variability of HbA1c. Multiple databases were searched from inception to November 2022 for follow-up studies of any design in adults or children, with repeated measures of HbA1c or glycosylated haemoglobin. Title and abstract screening was performed in duplicate, full text screening and data extraction by one reviewer and verified by a second. Risk of bias of included papers was assessed using a modified consensus-based standards for the selection of health measurement Instruments (COSMIN) tool. Intraclass correlation coefficient (ICC) results were pooled with a meta-analysis and coefficient of variation (CV) results were described by median and range.

RESULTS

Of 2675 studies identified, 111 met the inclusion criteria. Twenty-five studies reported variability data in healthy patients, 19 in patients with type 1 diabetes and 59 in patients with type 2 diabetes. Median within-subject coefficient of variation (CV) was 0.070 (IQR 0.034 to .09). For healthy subjects the median CV for HbA1c % was 0.017 (IQR 0.013 to 0.022), for patients with type 1 diabetes 0.084 (IQR 0.067 to 0.89) and for type 2 diabetes 0.083 (IQR 0.06 to 0.10). CV increased with mean population HbA1c.

LIMITATIONS

Assessment of variability was not the main aim of many of the included studies and some relevant papers may have been missed. Many included papers had few participants or few repeated measurements.

CONCLUSIONS

Within-subject variability of HbA1c is higher for patients with than without diabetes and increases with mean population HbA1c. This may confound observed relationships between HbA1c variability and health outcomes. Because of its importance in clinical decision-making there is a need for better estimates and understanding of factors associated with of HbA1c variability.

摘要

背景

糖化血红蛋白(HbA1c)的测量用于诊断和指导糖尿病的治疗。测量的 HbA1c 个体内变异性会影响其临床应用和解释,但尚无全面的系统综述描述个体内变异性。

方法

对 HbA1c 的个体内变异性进行了系统评价和荟萃分析。从成立到 2022 年 11 月,在多个数据库中搜索了任何设计的成人或儿童的随访研究,这些研究都对 HbA1c 或糖化血红蛋白进行了重复测量。通过两名评审员进行标题和摘要筛选,通过一名评审员进行全文筛选和数据提取,并由第二名评审员进行验证。使用改良的基于共识的健康测量仪器选择标准(COSMIN)工具评估纳入研究的偏倚风险。使用荟萃分析对组内相关系数(ICC)结果进行了汇总,并通过中位数和范围描述了变异系数(CV)结果。

结果

在确定的 2675 项研究中,有 111 项符合纳入标准。25 项研究报告了健康患者的变异性数据,19 项研究报告了 1 型糖尿病患者的变异性数据,59 项研究报告了 2 型糖尿病患者的变异性数据。个体内变异系数(CV)的中位数为 0.070(IQR 0.034 至 0.09)。健康受试者的 HbA1c%个体内 CV 的中位数为 0.017(IQR 0.013 至 0.022),1 型糖尿病患者为 0.084(IQR 0.067 至 0.89),2 型糖尿病患者为 0.083(IQR 0.06 至 0.10)。CV 随着人群 HbA1c 的平均值而增加。

局限性

许多纳入的研究并非主要评估变异性,因此可能遗漏了一些相关论文。许多纳入的论文参与者较少或重复测量次数较少。

结论

与无糖尿病患者相比,糖尿病患者的 HbA1c 个体内变异性更高,且随着人群 HbA1c 的平均值而增加。这可能会混淆 HbA1c 变异性与健康结果之间的观察到的关系。由于其在临床决策中的重要性,因此需要更好地估计和理解与 HbA1c 变异性相关的因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70ce/10395823/909a40a8c47c/pone.0289085.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验